News articles about Akers Biosciences (NASDAQ:AKER) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akers Biosciences earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 46.3622873425567 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Akers Biosciences (AKER) traded down 3.1840% during trading on Friday, reaching $0.9487. 67,096 shares of the company’s stock were exchanged. Akers Biosciences has a 52-week low of $0.85 and a 52-week high of $3.70. The firm’s market cap is $8.44 million. The stock’s 50 day moving average price is $1.06 and its 200 day moving average price is $1.34.

Akers Biosciences (NASDAQ:AKER) last posted its quarterly earnings data on Monday, August 14th. The medical instruments supplier reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.04. The company had revenue of $1.20 million during the quarter. Akers Biosciences had a negative return on equity of 59.94% and a negative net margin of 89.49%. Equities research analysts anticipate that Akers Biosciences will post ($0.25) EPS for the current fiscal year.

Separately, ValuEngine lowered shares of Akers Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, May 18th.

COPYRIGHT VIOLATION NOTICE: “Akers Biosciences (AKER) Earns News Sentiment Rating of 0.12” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://theolympiareport.com/2017/08/27/akers-biosciences-aker-earns-news-sentiment-rating-of-0-12.html.

Akers Biosciences Company Profile

Akers Biosciences, Inc, together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally. The company’s marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness.

Insider Buying and Selling by Quarter for Akers Biosciences (NASDAQ:AKER)

Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.